Immunotherapy is set to become the default treatment for the vast majority of lung cancer patients after a clinical trial from drugmaker Merck showed that adding its novel medicine to chemotherapy boosted survival.
制藥公司默克(Merck)的一項臨床試驗顯示，其研發的新藥物聯合化療會提高肺癌患者存活率，免疫療法將成為絕大多數肺癌患者的默認療法。
您已閱讀9%（280字），剩余91%（2918字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。